Valeant Pharmaceuticals disclosed late Wednesday that it was subpoenaed by U.S. prosecutors seeking information on its pricing programs. In early trading on Thursday, Valeant’s U.S.-listed shares were down 9% at $156.53. Valeant under fire for increasing drug prices Valeant Pharmaceuticals has received subpoenas from U.S. prosecutors seeking information on drug-pricing decisions. In a statement on Wednesday night, the Canada-based drug company said it recently received a subpoena from the U.S. Attorney’s Office in Massachusetts and another from the Manhattan U.S. Attorney’s Office seeking information on its patient assistance programs, drug distribution and pricing decisions. Laval, Quebec-based Valeant said the subpoenas mostly…
Valeant Pharmaceuticals Under Fresh Scrutiny Over Drug Pricing
Mani
Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports